Tivantinib Meets Study Endpoint
― ArQule Inc. and Daiichi Sankyo Co. Ltd. announced that a Phase 2 trial data using tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC) met its primary endpoint. Now the full results from this trial will be presented at the 2012 Annual Meeting of American Society of Clinical Oncology, including positive data in the pre-defined c-MET high population. Additional clinical data with tivantinib will be featured in two poster discussions and two [...].
